Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Shire On Course For 2017 Launch Of 'Adderall Beads' For Adult ADHD

This article was originally published in Scrip

Executive Summary

Shire's positive topline data from a pediatric Phase III trial of SHP465 (triple-bead mixed amphetamine salts) addresses the US FDA requirements for a class 2 resubmission for the product's NDA, said the company. The product is slated for US launch in 2017.


Related Content

Goal Finally In Sight For Shire's 'Adderall Beads' Extension Strategy